Financial Performance - The group's consolidated revenue for the year ended December 31, 2023, was approximately HKD 1,706,600,000, an increase of 29.5% compared to approximately HKD 1,317,700,000 in 2022[8]. - The group recorded a profit after tax of approximately HKD 275,300,000 for the year ended December 31, 2023, representing a 22.1% increase from approximately HKD 225,400,000 in 2022[8]. - The gross profit for the year was HKD 1,539,293,089, with a gross margin reflecting a strong operational efficiency[178]. - The net profit for the year was HKD 275,259,617, compared to HKD 225,411,310 in the previous year, showing an increase in profitability[178]. - Basic earnings per share increased to HKD 0.4827 from HKD 0.3927 in 2022, reflecting improved earnings performance[178]. - The overall comprehensive income for the year was HKD 244,925,110, a substantial increase from HKD 66,318,478 in 2022, indicating strong financial health[178]. - The total comprehensive income for the year ended December 31, 2023, was HKD 244,925,110, compared to a loss of HKD 132,597,063 in the previous year[183]. Cash and Assets - As of December 31, 2023, the group's cash and cash equivalents amounted to approximately HKD 509,800,000, down from approximately HKD 543,500,000 in 2022[9]. - The company reported a net cash outflow from financing activities of HKD 309,924,789 for the year ended December 31, 2023, compared to HKD 169,110,470 in the previous year[157]. - The cash and cash equivalents at the end of the year were HKD 509,845,284, down from HKD 543,486,017 at the end of the previous year[157]. - Total assets amounted to HKD 2,827,558,498, with total liabilities of HKD 903,781,273, resulting in a net asset value of HKD 1,923,777,225[180]. - The company reported a significant increase in non-current assets, totaling HKD 1,582,280,872, compared to HKD 1,498,418,728 in the previous year[180]. - The total equity as of December 31, 2023, was HKD 1,923,777,225, reflecting a stable financial position[183]. Research and Development - The group has 16 research and development projects in various stages, with 4 ophthalmology projects currently in clinical stages, identified as mid-term growth drivers[6]. - The core product, Elysium®, has become a significant growth driver for the group, acquired in March 2022, including its intellectual property and marketing rights[11]. - The company holds a total of 84 patent certificates, including 63 invention patents, indicating a strong focus on innovation[194]. - The company aims to enhance its R&D capabilities and position in the ophthalmology field through a five-year development plan initiated in 2021[193]. - The company is focusing on the development of a new gel formulation of bovine alkaline fibroblast growth factor for eye use, indicating ongoing innovation in product offerings[199]. - The company is committed to improving product efficacy and safety, as evidenced by the development of preservative-free options[199]. Market Expansion and Product Development - The group is actively pursuing market expansion and new product development strategies to enhance its competitive position in the biotechnology sector[6][11]. - The group aims to expand its market presence in lower-tier cities in China and cultivate pharmacies as auxiliary sales channels[59]. - The company is expanding its product line with the introduction of lecithin-iodine complex capsules, aiming to capture a broader market segment[200]. - The company is also launching absorbable dressings, which may enhance its presence in the medical supplies market[200]. - The company is exploring new market opportunities through the introduction of various health-related products, including mouthwash for dental care[200]. Corporate Governance and Shareholder Information - The independent auditor's report confirmed that the financial statements reflect a true and fair view of the company's financial position as of December 31, 2023[140]. - The company has maintained sufficient public float throughout the review year and as of the report date[92]. - As of December 31, 2023, major shareholders include Yan Mingjie with 152,020,667 shares (26.78%) and Liu Huijuan with 153,945,667 shares (27.12%) of the company's ordinary shares[109]. - The company has proposed a final dividend of HKD 25,541,325 for the review year[75]. - The board has proposed a final dividend of HKD 0.045 per share, up from HKD 0.025 per share in the previous year, bringing the total dividend for 2023 to HKD 0.09 per share[197]. Environmental and Social Responsibility - The group is committed to creating an environmentally friendly work environment by promoting energy conservation and recycling initiatives[19]. - The company made charitable donations totaling approximately HKD 481,000 during the review period, down from HKD 983,000 in 2022[96]. - The group emphasizes the importance of human resources as a key asset and aims to continue being an attractive employer[25].

亿胜生物科技（1061.HK） 2024-03-19 星期二 ➢ 2023 年营收利润快速增长 相关报告 整体来看，公司的眼科+外科产品均有增长动力，在复杂环境下的产 品盈利能力仍能保持稳定。核心业务中，眼科贝复舒单剂量滴眼液有 望快速增长，公司目标未来在贝复舒产品实现营收 10 亿港元。2022 年初公司顺利收购适丽顺卵磷脂络合碘胶囊，2023 年营收 1.6 亿港 元，同比增长 17.4%，占总营收 9.4%，适丽顺具有独特的药理作用， 适应症广泛，疗效受到医生及患者普遍认可，是眼底药的稀缺品种。 外科方面，2023 年贝复新系列大力开拓医美领域，由于生长因子类体 表创伤药物市场规模仍保持高速发展，因此公司在该产品的未来预期 仍保持乐观。 公司与复宏汉霖共同开发的贝伐珠单抗已经在美国、欧盟、中国、澳 大利亚进行三期临床，且已于美国 FDA 完成首例患者给药。预计于 2025 年递交新药申请。目前全球上市贝伐珠单抗产品均无湿性 AMD 适应症，市场挖掘空间广阔。公司从 Mitotech 获得 SkQ1 滴眼液全球 独家权益，目前正在进行 SkQ1 的美国三期临床试验，通过 VISTA-1 和 VISTA-2 ...

二零二四年三月十八日 按金及預付款項並不包括已減值資產，而其賬面值與其公平值相若。 • 通過醫療科技創新平台，為慢性病患者提供網上會診及開具電子處方。 －非上市股本投資（附註(c)） 366,251 2,060,452 為使本集團於乾眼症領域之美國藥監局VISTA計劃的持續發展具有靈活性及獨立性並使本集 團能夠進一步探索開發其他眼科適應症的眼科產品以滿足全球（定義見下文）市場的臨床及商 業需求，於二零二二年十月十三日，本集團自Mitotech成功獲得眼科領域與SkQ1相關的(i)專利 轉讓契據（「專利轉讓契據」）；及(ii)專利及專有技術許可協議（「專利及專有技術許可協議」）。 回顧年度的行政開支為約217,000,000港元，而二零二二年則為約156,000,000港元。行政開支增 加主要是由於(i)擴展美國及新加坡業務以及成立線上醫療諮詢平台的成本增加約8,400,000港 元；(ii)研發開支增加約15,600,000港元；及(iii)其他無形資產攤銷增加約10,900,000港元。 附註： 截至二零二三年十二月三十一日止年度 全年業績公佈 財務摘要 1 流動比率：流動資產總值╱流動負債總額 2 資產負 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was HKD 899,359,000, representing a 37.1% increase from HKD 655,825,000 in the same period of 2022[18]. - Gross profit for the period was HKD 810,462,000, up 38.2% from HKD 586,644,000 year-over-year[18]. - Net profit for the period was HKD 169,811,000, an increase of 21.9% compared to HKD 139,231,000 in the previous year[18]. - Basic earnings per share rose to HKD 0.2972 from HKD 0.2421, reflecting a growth of 22.8%[18]. - The company reported a total comprehensive income of HKD 94,632,000 for the six months ended June 30, 2023[39]. - The company reported a pre-tax profit of HKD 204,855,000 for the first half of 2023, compared to HKD 162,701,000 in the same period of 2022, marking an increase of approximately 26.0%[52]. - Profit for the period increased by 22.0% to approximately HKD 169.8 million, up from approximately HKD 139.2 million in the previous year[165]. - Revenue from the ophthalmology segment was approximately HKD 381.6 million, a 41.6% increase year-on-year, while the surgical segment recorded approximately HKD 517.8 million, a 34.0% increase[174]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to HKD 2,829,122,000, compared to HKD 2,712,397,000 at the end of 2022, indicating a 4.3% increase[9]. - Current assets increased to HKD 1,337,241,000 from HKD 1,213,978,000, marking a growth of 10.2%[9]. - Total liabilities were HKD 1,021,071,000, up from HKD 981,030,000, which is a 4.1% increase[9]. - The company reported a total equity of HKD 1,808,051,000, compared to HKD 1,731,367,000, reflecting a growth of 4.4%[9]. - The company’s total liabilities increased to HKD 456,370,000 as of June 30, 2023, from HKD 416,326,000 as of December 31, 2022, indicating a rise of approximately 10%[104]. Cash Flow - The net cash generated from operating activities was HKD 155,006,000, down from HKD 230,392,000 in the previous year, indicating a decrease of approximately 32.6%[42]. - The net cash used in investing activities was HKD 106,799,000, compared to HKD 143,617,000 in the prior period, showing an improvement of about 25.6%[44]. - The net cash used in financing activities was HKD 71,619,000, a decrease from HKD 94,588,000 in the same period last year, representing a reduction of approximately 24.3%[44]. - The total cash and cash equivalents at the end of the period were HKD 505,722,000, down from HKD 641,136,000 at the end of June 2022, a decline of about 21.1%[44]. - The company has cash and cash equivalents of approximately HKD 505.7 million as of June 30, 2023, down from approximately HKD 543.5 million at the end of 2022[171]. Share Repurchase and Dividends - The company repurchased a total of 1,019,000 shares from March to June 2023, with a total expenditure of HKD 3,681,320[25]. - The repurchase aims to enhance the company's net asset value per share and earnings per share for the benefit of all shareholders[25]. - The company plans to continue its strategy of share repurchases to support shareholder value[25]. - The company declared an interim dividend of HKD 0.045 per share, compared to HKD 0.04 per share in the previous year[74]. Research and Development - Research and development costs recognized as expenses were HKD 20,250, significantly higher than HKD 11,606 in the previous year[71]. - Research and development expenses totaled approximately HKD 90.3 million, representing 10.0% of revenue, a significant decrease from 30.1% in the previous year[176]. - The company has initiated a five-year R&D plan to enhance its capabilities and position in the ophthalmic field, focusing on growth factors, antibodies, and drug formulation technologies[155]. - As of June 30, 2023, there are 16 research and development programs in various stages, with 4 ophthalmic programs currently in clinical stages[157]. Market Presence and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[18]. - The company has established a network of 43 regional sales offices in China, employing over 1,200 sales personnel and marketing representatives as of June 30, 2023[154]. - The company has expanded its business in Singapore to serve as a base for market channel expansion in Southeast Asia[154]. - The group is focusing on expanding into new therapeutic areas such as oncology, orthopedics, and neurology through strategic investments[132]. Legal and Governance - The company is in a legal dispute with the main contractor regarding the construction of its second factory, with assets worth approximately HKD 42.9 million frozen as part of the litigation[164]. - The company is committed to enhancing corporate governance and transparency in its operations[26]. Convertible Loans - The total amount of convertible loans issued by the company was approximately HKD 25,300,000, with a 5% annual interest rate, maturing on September 30, 2023[83]. - The company extended the maturity date of a convertible loan of approximately HKD 35,300,000 to July 31, 2024, with a 5% annual interest rate[81]. - The outstanding principal amount of the convertible loan was HKD 150,000,000, with no part converted into shares[180]. - If the convertible loan were fully converted at an initial conversion price of HKD 5.90 per share, it would result in the issuance of approximately 25,423,728 shares[181].

接下来我很荣幸的向大家介绍出席本次业绩发布会的管理层他们是主席闫明炽先生大家好董事总经理方海舟先生大家好副董事总经理闫贤龙先生大家好首席财务总监邱丽文女士Hello 刚才主持人也介绍了一下益胜的基本情况我在这里再强调一下其实益胜是作为一家生物科技企业我们是拥有先进的和成熟的产品以及有很好的经营性先进比例 还有也拥有全流程的生物原料制剂的生产平台涵盖向低盐液 沿用凝胶 外用凝胶 液体制剂 动钢制剂等也有一系列吹逛风的单气炼平台 也成为了一家口腔科后面一系列的产品在新加坡的独家销售代理同时我们也发布了一项在家用官僚治疗高端品牌叫佩特 那么这个应该是充分的利用了医生在眼科跟外科这些优势我们是不断的获取产品来提高我们的收入跟利润医生的核心业务其实大家刚才也介绍过主要是有眼科和外科两个部分组成那么眼科的这个业务其实现在应该说是已经涵盖了我们从眼表 那么这个就是现在应该说艺术已经基本上打造起一个完整的这个眼科的产品组合那在这在大家在器械方面我们也含有一系列在这个像钢眼的器械还在布置之中对那么眼科的产品大家最突出的就是我们的背弧术系列那背弧术系列呢应该说经过了不断的 那么可见他的在目前的知名度和美意度以及临床的认可度也是非 ...

| --- | --- | --- | --- | |------------------------------------|-------|----------------------------------------|------------------------------------------| | | | 於二零二三年 \n六月三十日 （未經審核） | 於二零二二年 \n十二月三十一日 （經審核） | | | 附註 | 千港元 | 千港元 | | 非流動資產 | | | | | 物業、廠房及設備 | 12 | 369,274 | 398,835 | | 使用權資產 | | 1,170 | 2,278 | | 土地使用權 | | 14,446 | 15,330 | | 商譽 | | 54,773 | 57,147 | | 其他無形資產 | 13 | 998,994 | 978,697 | | 於聯營公司之投資 | | 1,957 | 2,631 | | | | | | | 應收可換股貸款 | 14 | 11,277 | 10,545 | | 按公平值計入其他全面收益之財務資產 | 15 | 3 ...

ESSEX BIO-TECHNOLOGY LIMITED 億 勝 生 物 科 技 有 限 公 司 (於開曼群島註冊成立之有限公司) (股份代號: 1061) 年 報 全球 生物再生科技 創先者 ESSEX /ZHI - 再生未來 (5) | --- | --- | |--------------------------|-------| | | | | | | | | 目錄 | | | | | 主席報告 | 2 | | 業務回顧 | 10 | | 財務摘要 | 20 | | 財務回顧 | 21 | | 董事及高級管理層履歷 | 28 | | 董事會報告 | 31 | | 獨立核數師報告 | 53 | | 綜合損益及其他全面收益表 | 57 | | 綜合財務狀況表 | 58 | | 綜合權益變動表 | 59 | | 綜合現金流量表 | 60 | | 綜合財務報表附註 | 62 | | 五年財務概要 | 132 | | 企業管治報告 | 133 | | 公司資料 | 146 | 主席報告 (ESSEX) 1Z用主 目錄 目錄 - - - - - - 嚴名熾 主席 於回顧年度，由於二零二二年大部分時間內COVID- ...

尊敬的各位投资者,大家上午好欢迎各位出席益省生物科技2022年度业绩线上发布会益省生物科技有限公司是一间专注于研发生产和销售基因工程药物BBFGF FGF-2的生物制药企业 强调一下那益盛的发展愿景呢就是成为眼科和这个创商吸附的领先者全球总流领域的重要参与者那么益盛现在的这个企业的价值亮点应该有下面四个方面第一个已经是拥有非常成熟的产品这个市场推广能力在生产因子领域呢是占据的领先地位企业也拥有也拥有非常稳定的先进流 从我们在中国医药市场的占有率就来看应该说我们在全球生产因子领域是个领导者目前虽然说这几年受到疫情的一些影响但是我们还是稳稳地站稳了市场的领导地位 市场占有率也达到了38.7%应该说比前一年增的35%提高了3.7个百分点应该说可以看出来就是益生其实在生产因子这个领域其实在中国是稳拿了龙头地位并且市场地位也是越来越稳固 2022年受到疫情的影响 确实我们在2022年的业绩是有一定的下降比如说2022年是下降了20% 销售收入是下降20% 达到了13.18亿 一个收购所产生的2500万的资产减值也是差不多就占到下降幅度的7.5%还有些汇率因素的影响就是这个可能一个加起来差不多有10%的一次性的这些影响因 ...

Financial Performance - Revenue for the six months ended June 30, 2022, was HKD 655,825,000, a decrease of 11.1% compared to HKD 737,374,000 for the same period in 2021[10]. - Gross profit for the period was HKD 586,644,000, down 5.8% from HKD 622,694,000 year-on-year[10]. - The company reported a net profit of HKD 139,231,000, representing a decline of 14.1% from HKD 162,186,000 in the previous year[10]. - The total comprehensive income for the six months ended June 30, 2022, was HKD 46,030,000, compared to HKD 180,212,000 for the same period in 2021, representing a decrease of approximately 74.5%[14]. - Cash generated from operating activities for the six months ended June 30, 2022, was HKD 180,085,000, down from HKD 205,156,000 in the previous year, indicating a decline of about 12.2%[16]. - The reported profit before tax for the six months ended June 30, 2022, was HKD 162,701,000, compared to HKD 183,074,000 for the same period in 2021, representing a decrease of approximately 11.5%[26]. - The group recorded a consolidated revenue of approximately HKD 655.8 million for the six months ended June 30, 2022, a decrease of 11.1% compared to the same period last year[117]. - The group's profit decreased by 14.2% to approximately HKD 139.2 million, down from approximately HKD 162.2 million in the same period last year, primarily due to COVID-19 restrictions impacting outpatient operations in Chinese hospitals[118]. Assets and Liabilities - Total assets as of June 30, 2022, amounted to HKD 2,794,303,000, a decrease from HKD 2,863,439,000 at the end of 2021[12]. - Current liabilities decreased to HKD 621,173,000 from HKD 689,585,000, indicating improved liquidity management[12]. - The total liabilities decreased from HKD 1,742,906,000 as of June 30, 2021, to HKD 1,577,353,000 as of June 30, 2022, indicating a reduction of approximately 9.5%[14]. - The company’s cash and cash equivalents stood at HKD 641,136,000, down from HKD 671,336,000 at the end of 2021[12]. - The company’s total liabilities decreased from HKD 1,259,471,000 as of December 31, 2021, to HKD 1,422,203,000 as of June 30, 2022, indicating a change in financial structure[30]. - The debt-to-asset ratio as of June 30, 2022, was 37.6%, a decrease from 39.4% as of December 31, 2021, reflecting improved financial stability[137]. Cash Flow and Investments - The net cash used in investing activities for the six months ended June 30, 2022, was HKD 143,617,000, compared to HKD 119,463,000 in the same period of 2021, reflecting an increase of approximately 20.2%[18]. - The company reported a decrease in cash and cash equivalents of HKD 7,813,000 for the six months ended June 30, 2022, compared to an increase of HKD 52,673,000 in the same period of 2021[18]. - The company has capital commitments of 73,814,000 HKD for development costs and 211,251,000 HKD for acquired intangible assets as of June 30, 2022[94]. - The company secured bank financing of approximately HKD 629.7 million, with around HKD 505.8 million already utilized as of June 30, 2022[137]. Shareholder Information - The company paid dividends amounting to HKD 31,610,000 during the six months ended June 30, 2022[18]. - The company declared an interim dividend of HKD 0.04 per ordinary share for the six months ended June 30, 2022, consistent with the previous year[40]. - The company aims to enhance shareholder value through share repurchases to improve net asset value per share and earnings per share[187]. - Major shareholders include Yan Ming Chi with 153,945,667 shares (26.81%) and Liu Hui Juan with 153,945,667 shares (26.81%) as of June 30, 2022[176][183]. Research and Development - Research and development costs recognized as expenses amounted to HKD 11,606,000 for the six months ended June 30, 2022, compared to HKD 11,080,000 for the same period in 2021[36]. - The group has initiated a five-year R&D plan (2021-2025) to enhance its R&D capabilities and position in the ophthalmology field[110]. - The group has 15 R&D projects in various stages, with three ophthalmology projects currently in clinical stages, viewed as mid-term growth drivers[112]. Market and Product Development - The estimated number of moderate to severe dry eye patients in China exceeded 117 million in 2019, indicating a significant market potential for the SkQ1 product[103]. - The estimated number of patients for the four types of conditions treatable by the anti-VEGF licensed product in China exceeded 15.5 million in 2019[105]. - The bFGF product series accounted for approximately 86.5% of the total revenue during the review period[98]. Corporate Governance - The company maintained compliance with the corporate governance code throughout the review period[189]. - All directors confirmed compliance with the code of conduct regarding securities trading for the six months ended June 30, 2022[194].

(ESSEX)亿胜 ESSEX BIO-TECHNOLOGY LIMITED 億 勝 生 物 科 技 有 限 公 司 (於開曼群島註冊成立之有限公司) (股份代號 : 1061) 2021 # * 生物再生科技 (ESSEX)亿胜 a 1947 億勝科技 再生未來 目錄 目錄 1 億勝生物科技有限公司 | --- | --- | |-------|--------------------------| | | 目錄 | | 2 | 主席報告 | | 10 | 業務回顧 | | 20 | 財務摘要 | | 21 | 財務回顧 | | 29 | 董事及高級管理層履歷 | | 32 | 董事會報告 | | 53 | 獨立核數師報告 | | 58 | 綜合損益及其他全面收益表 | | 59 | 綜合財務狀況表 | | 60 | 綜合權益變動表 | | 61 | 綜合現金流量表 | | 63 | 綜合財務報表附註 | | 130 | 五年財務概要 | | 131 | 企業管治報告 | | 142 | 公司資料 | 主席報告 主席報告 2 嚴名熾 主席 主席報告 本人代表億勝生物科技有限公司（「本公司」，連同其附屬公司統 ...